Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Influence of Sarcopenia on Mortality and Disease Progression in Hepatocellular Carcinoma Treated With Ablation, Embolization and Sorafenib
Authors not listed
Sohag University · 2024
Abstract
Liver cancer poses a major threat to the global cancer burden, and the number of deaths is estimated to be more than one million annually by 2030. Locoregional therapies such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and radiation are associated with improved survival and quality of life for patients with unresectable HCC \[Couri and Pillai, 2019\]. However, curative therapies or locoregional therapies are not applicable to approximately 50% of HCC cases who are diagnosed at an advanced stage and have progression with transarterial therapies \[Park et al., 2015\]. For these patients, sorafenib, lenvatinib, and atezolizumab combined with bevacizumab have been approved as the first-line systemic therapy \[Fan et al., 2022\].
Sarcopenia is a progressive and generalized skeletal muscle disease characterized by accelerated loss of muscle mass and function \[Cruz-Jentoft and Sayer, 2019\]. It has been associated with higher mortality among the general population and patients with cancer. This study aims to assess the possible role of sarcopenia in predicting the outcome of HCC patients following a variety of treatments including local ablation, TACE and sorafenib.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-24 MST
Cite this
APA
Anonymous. (2024). Influence of Sarcopenia on Mortality and Disease Progression in Hepatocellular Carcinoma Treated With Ablation, Embolization and Sorafenib. <em>Sohag University</em>. https://clinicaltrials.gov/study/NCT06177496
Vancouver
Anonymous. Influence of Sarcopenia on Mortality and Disease Progression in Hepatocellular Carcinoma Treated With Ablation, Embolization and Sorafenib. Sohag University. 2024.
BibTeX
@misc{anon2024Influe,
title = {Influence of Sarcopenia on Mortality and Disease Progression in Hepatocellular Carcinoma Treated With Ablation, Embolization and Sorafenib},
author = {Anonymous},
journal = {Sohag University},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IRCCS Azienda Ospedaliero-Universitaria di Bologna 2022
Open access · US-GOV
Prognostic Model of Survival of Patients With Hepatocarcinoma and Sarcopenia Treated With Systemic Therapy
Cancers 2021
Open access · CC-BY
The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
Fudan University 2020
Open access · US-GOV
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer (Stage IA to IIIA)
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013
Open access · OA
Anoikis molecular pathways and its role in cancer progression
International Journal of Molecular Sciences 2023
Open access · CC-BY
Polyamines and Physical Activity in Musculoskeletal Diseases: A Potential Therapeutic Challenge
Molecular and Cellular Biology 2017
Open access · OA